In recent years MTHFD2 has emerged as an attractive anticancer drug target as it is upregulated in cancer but is virtually absent in healthy adult cells.[10, 30, 33, 34] Selective targeting of MTHFD2 could result in anticancer therapies with reduced side‐effects. Here, MTHFD2 is linked to cancer.